Compass raises $80M to take [synthetic psilocybin] drug toward phase 3
The London-based biotech is advancing the drug, [one of the many] active ingredient[s] in magic mushrooms … Compass has partnered with academic centers, primarily in the U.S.
…is advancing the clinical program while also working on earlier-stage projects. The biotech… focuse[s] on psilocybin therapy in the belief it could leverage existing knowledge of the drug to quickly get a new product to patients with treatment-resistant depression. Yet, Wilde sees the company as “relatively treatment agnostic.”… “While psilocybin is a great starting point… we think that based on the learnings that we have generated in our preclinical and mechanistic work we will be able to develop even better medications.”
Original Article (Fierce Bio-tech):
Compass raises $80M to take magic mushroom drug toward phase 3
Artwork Fair Use: MatasNavickas